Ionis Pharmaceuticals Inc (IONS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has a cash flow conversion efficiency ratio of -0.213x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-131.44 Million) by net assets ($617.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ionis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how Ionis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ionis Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Ionis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
0.084x |
|
CARLSBERG B DK20 ADR 1/5
F:CBGC
|
N/A |
|
Sociedad Quimica y Minera de Chile SA ADR B
NYSE:SQM
|
0.078x |
|
TELE2 AB UNSP.ADR/1/2 B
F:NCY
|
N/A |
|
Equity Lifestyle Properties Inc
NYSE:ELS
|
0.081x |
|
HubSpot Inc
NYSE:HUBS
|
0.101x |
|
Guangdong Haid Group Co Ltd
SHE:002311
|
0.076x |
|
The Cooper Companies, Inc
NASDAQ:COO
|
0.031x |
Annual Cash Flow Conversion Efficiency for Ionis Pharmaceuticals Inc (1991–2024)
The table below shows the annual cash flow conversion efficiency of Ionis Pharmaceuticals Inc from 1991 to 2024. For the full company profile with market capitalisation and key ratios, see IONS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $588.35 Million | $-500.95 Million | -0.851x | -7.07% |
| 2023-12-31 | $386.69 Million | $-307.51 Million | -0.795x | -66.05% |
| 2022-12-31 | $572.89 Million | $-274.37 Million | -0.479x | -1300.46% |
| 2021-12-31 | $772.00 Million | $30.80 Million | 0.040x | -6.30% |
| 2020-12-31 | $843.00 Million | $35.89 Million | 0.043x | -79.25% |
| 2019-12-31 | $1.69 Billion | $345.72 Million | 0.205x | -59.60% |
| 2018-12-31 | $1.19 Billion | $602.89 Million | 0.508x | +22.10% |
| 2017-12-31 | $418.72 Million | $174.15 Million | 0.416x | +136.94% |
| 2016-12-31 | $99.56 Million | $-112.11 Million | -1.126x | -1170.20% |
| 2015-12-31 | $200.79 Million | $21.12 Million | 0.105x | +331.52% |
| 2014-12-31 | $257.78 Million | $6.29 Million | 0.024x | -85.47% |
| 2013-12-31 | $378.39 Million | $63.49 Million | 0.168x | +1534.74% |
| 2012-12-31 | $182.77 Million | $1.88 Million | 0.010x | +101.53% |
| 2011-12-31 | $171.43 Million | $-114.80 Million | -0.670x | -157.51% |
| 2010-12-31 | $244.54 Million | $-63.59 Million | -0.260x | +27.56% |
| 2009-12-31 | $302.06 Million | $-108.44 Million | -0.359x | -117.65% |
| 2008-12-31 | $104.25 Million | $212.03 Million | 2.034x | -42.28% |
| 2007-12-31 | $10.24 Million | $36.09 Million | 3.524x | +748.16% |
| 2006-12-31 | $97.90 Million | $-53.23 Million | -0.544x | +97.65% |
| 2005-12-31 | $2.67 Million | $-61.74 Million | -23.167x | -1742.37% |
| 2004-12-31 | $-72.13 Million | $-101.75 Million | 1.411x | +199.25% |
| 2003-12-31 | $67.18 Million | $-95.47 Million | -1.421x | -134.12% |
| 2002-12-31 | $155.48 Million | $-94.38 Million | -0.607x | -2099.26% |
| 2001-12-31 | $223.10 Million | $-6.16 Million | -0.028x | +92.10% |
| 2000-12-31 | $66.37 Million | $-23.19 Million | -0.349x | +99.42% |
| 1999-12-31 | $800.00K | $-48.40 Million | -60.500x | -832.28% |
| 1998-12-31 | $-4.20 Million | $-34.70 Million | 8.262x | +1499.71% |
| 1997-12-31 | $34.90 Million | $-20.60 Million | -0.590x | -62.60% |
| 1996-12-31 | $58.40 Million | $-21.20 Million | -0.363x | -82.47% |
| 1995-12-31 | $75.90 Million | $-15.10 Million | -0.199x | +39.79% |
| 1994-12-31 | $46.00 Million | $-15.20 Million | -0.330x | -26.34% |
| 1993-12-31 | $58.50 Million | $-15.30 Million | -0.262x | +46.34% |
| 1992-12-31 | $39.80 Million | $-19.40 Million | -0.487x | -1820.50% |
| 1991-12-31 | $59.10 Million | $-1.50 Million | -0.025x | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe… Read more